Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EMBC
BUYEmbecta Corp. · Healthcare · United States · $195M · Avg Vol: $7M/d
COMPANY DESCRIPTION
Embecta Corp. is a pure-play global medical device company dedicated exclusively to diabetes care, offering a comprehensive portfolio of insulin delivery solutions including pen needles and syringes. Spun off from Becton Dickinson, the company holds a leading market position globally, leveraging extensive distribution networks and established brand trust among patients and healthcare providers. This specialized focus ensures deep expertise and market penetration in a critical healthcare segment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.1B | 1.1B | -1.5% | 1.0B | 1.0B | 1.1B | 0.2% |
| EPS | 3.92 | 1.23 | 1.36 | 1.64 | -25.2% | 1.89 | 0.89 | 0.97 | -23.2% |
| Shares | 57.1M | 57.3M | 57.7M | 58.5M | +2.5% | 59.3M | — | — | — |
| Debt | 1.6B | 1.6B | 1.6B | 1.4B | -4.5% | 1.4B | — | — | — |
| Equity | -891.4M | -821.7M | -738.9M | -651.2M | — | — | — | — | — |
| Op CF | 412.2M | 67.7M | 35.7M | 191.7M | -22.5% | 213.5M | — | — | — |
| Inv CF | -24.0M | -26.5M | -15.8M | -9.3M | — | — | — | — | — |
| Fin CF | -48.0M | -48.7M | -73.4M | -226.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EMBC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EMBC | Embecta Corp.(you) | $195M | 74 | BUY |
| SMTI | Sanara MedTech Inc. | $234M | 60 | HOLD |
| PDEX | Pro-Dex, Inc. | $175M | 91 | STRONG BUY |
| UTMD | Utah Medical Products, Inc. | $214M | 97 | STRONG BUY |
| OSUR | OraSure Technologies, Inc. | $273M | 48 | HOLD |
| ANGO | AngioDynamics, Inc. | $562M | 58 | HOLD |
| KRMD | KORU Medical Systems, Inc. | $176M | 27 | SELL |
| LMAT | LeMaitre Vascular, Inc. | $2.2B | 76 | BUY |
| XRAY | DENTSPLY SIRONA Inc. | $2.6B | 74 | BUY |
| DXR | Daxor Corporation | $61M | 44 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%